Eniluracil Hand Foot Syndrome
|ClinicalTrials.gov Identifier: NCT00827580|
Recruitment Status : Completed
First Posted : January 23, 2009
Last Update Posted : August 28, 2009
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer Colon Cancer||Drug: Eniluracil Drug: Capecitabine||Phase 1|
- To estimate the frequency of HFS following treatment with capecitabine as modulated by the unilateral local application of eniluracil containing ointment.
- To assess any eniluracil dose response relationship in prevention of HFS.
- To evaluate any potential toxicity of eniluracil ointment.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||35 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Pilot Study of Eniluracil Containing Ointment for Prevention of Hand Foot Syndrome (HRS) Following Capecitabine (Xeloda)|
|Study Start Date :||January 2009|
- the frequency of HFS; evaluation of eniluracil dose response; and assessment of any toxicity related to the topical product.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00827580
|United States, West Virginia|
|Clinical Trials Research Unit, West Virginia University|
|Morgantown, West Virginia, United States, 226506|
|Principal Investigator:||William P. Petros, Pharm D||West Virginia University|